PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
VTGN vs. ACRV
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between VTGN and ACRV is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

VTGN vs. ACRV - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in VistaGen Therapeutics, Inc. (VTGN) and Acrivon Therapeutics Inc. Common Stock (ACRV). The values are adjusted to include any dividend payments, if applicable.

-40.00%-20.00%0.00%20.00%40.00%SeptemberOctoberNovemberDecember2025February
-18.94%
-28.63%
VTGN
ACRV

Key characteristics

Sharpe Ratio

VTGN:

-0.83

ACRV:

0.37

Sortino Ratio

VTGN:

-1.29

ACRV:

1.57

Omega Ratio

VTGN:

0.87

ACRV:

1.18

Calmar Ratio

VTGN:

-0.45

ACRV:

0.49

Martin Ratio

VTGN:

-1.20

ACRV:

1.48

Ulcer Index

VTGN:

36.73%

ACRV:

28.52%

Daily Std Dev

VTGN:

52.86%

ACRV:

113.01%

Max Drawdown

VTGN:

-99.20%

ACRV:

-85.34%

Current Drawdown

VTGN:

-98.70%

ACRV:

-77.76%

Fundamentals

Market Cap

VTGN:

$79.91M

ACRV:

$152.88M

EPS

VTGN:

-$0.74

ACRV:

-$2.66

Total Revenue (TTM)

VTGN:

$464.30K

ACRV:

$0.00

Gross Profit (TTM)

VTGN:

$464.30K

ACRV:

-$424.00K

EBITDA (TTM)

VTGN:

-$37.26M

ACRV:

-$64.02M

Returns By Period

In the year-to-date period, VTGN achieves a -7.12% return, which is significantly higher than ACRV's -14.29% return.


VTGN

YTD

-7.12%

1M

-6.48%

6M

-16.46%

1Y

-44.08%

5Y*

-32.57%

10Y*

N/A

ACRV

YTD

-14.29%

1M

-6.35%

6M

-26.50%

1Y

41.76%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

VTGN vs. ACRV — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VTGN
The Risk-Adjusted Performance Rank of VTGN is 1212
Overall Rank
The Sharpe Ratio Rank of VTGN is 77
Sharpe Ratio Rank
The Sortino Ratio Rank of VTGN is 77
Sortino Ratio Rank
The Omega Ratio Rank of VTGN is 1111
Omega Ratio Rank
The Calmar Ratio Rank of VTGN is 2020
Calmar Ratio Rank
The Martin Ratio Rank of VTGN is 1515
Martin Ratio Rank

ACRV
The Risk-Adjusted Performance Rank of ACRV is 6565
Overall Rank
The Sharpe Ratio Rank of ACRV is 6060
Sharpe Ratio Rank
The Sortino Ratio Rank of ACRV is 7171
Sortino Ratio Rank
The Omega Ratio Rank of ACRV is 6666
Omega Ratio Rank
The Calmar Ratio Rank of ACRV is 6767
Calmar Ratio Rank
The Martin Ratio Rank of ACRV is 6262
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

VTGN vs. ACRV - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for VistaGen Therapeutics, Inc. (VTGN) and Acrivon Therapeutics Inc. Common Stock (ACRV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for VTGN, currently valued at -0.83, compared to the broader market-2.000.002.004.00-0.830.37
The chart of Sortino ratio for VTGN, currently valued at -1.29, compared to the broader market-6.00-4.00-2.000.002.004.00-1.291.57
The chart of Omega ratio for VTGN, currently valued at 0.87, compared to the broader market0.501.001.502.000.871.18
The chart of Calmar ratio for VTGN, currently valued at -0.53, compared to the broader market0.002.004.006.00-0.530.49
The chart of Martin ratio for VTGN, currently valued at -1.20, compared to the broader market0.0010.0020.0030.00-1.201.48
VTGN
ACRV

The current VTGN Sharpe Ratio is -0.83, which is lower than the ACRV Sharpe Ratio of 0.37. The chart below compares the historical Sharpe Ratios of VTGN and ACRV, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.00SeptemberOctoberNovemberDecember2025February
-0.83
0.37
VTGN
ACRV

Dividends

VTGN vs. ACRV - Dividend Comparison

Neither VTGN nor ACRV has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

VTGN vs. ACRV - Drawdown Comparison

The maximum VTGN drawdown since its inception was -99.20%, which is greater than ACRV's maximum drawdown of -85.34%. Use the drawdown chart below to compare losses from any high point for VTGN and ACRV. For additional features, visit the drawdowns tool.


-80.00%-75.00%-70.00%-65.00%-60.00%SeptemberOctoberNovemberDecember2025February
-79.00%
-77.76%
VTGN
ACRV

Volatility

VTGN vs. ACRV - Volatility Comparison

The current volatility for VistaGen Therapeutics, Inc. (VTGN) is 9.89%, while Acrivon Therapeutics Inc. Common Stock (ACRV) has a volatility of 29.52%. This indicates that VTGN experiences smaller price fluctuations and is considered to be less risky than ACRV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%SeptemberOctoberNovemberDecember2025February
9.89%
29.52%
VTGN
ACRV

Financials

VTGN vs. ACRV - Financials Comparison

This section allows you to compare key financial metrics between VistaGen Therapeutics, Inc. and Acrivon Therapeutics Inc. Common Stock. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab